Halozyme Therapeutics Added to Russell 1000® Index
Halozyme Therapeutics (NASDAQ: HALO) has announced its addition to the U.S. large-cap Russell 1000® Index, effective after market close on June 27th, 2025, as part of FTSE Russell's annual index reconstitution. The Russell 1000® Index comprises approximately 1,000 of the largest U.S. securities based on market capitalization and serves as a key benchmark for large-cap stock performance.
According to CEO Dr. Helen Torley, this inclusion reflects the company's leadership in rapid large-volume subcutaneous drug delivery and their track record of durable top-and-bottom line growth. The membership in the Russell 1000® Index will remain in place for one year.
Halozyme Therapeutics (NASDAQ: HALO) è stata inclusa nell'indice statunitense Russell 1000® per le grandi capitalizzazioni, a partire dalla chiusura del mercato del 27 giugno 2025, nell'ambito della ricostituzione annuale dell'indice di FTSE Russell. Il Russell 1000® comprende circa 1.000 delle maggiori società statunitensi in base alla capitalizzazione di mercato ed è un importante punto di riferimento per la performance delle azioni a grande capitalizzazione.
Secondo la CEO, la Dott.ssa Helen Torley, questa inclusione testimonia la leadership dell'azienda nella rapida somministrazione sottocutanea di grandi volumi di farmaci e il loro storico di crescita solida sia nei ricavi che nei profitti. L'appartenenza al Russell 1000® durerà un anno.
Halozyme Therapeutics (NASDAQ: HALO) ha anunciado su incorporación al índice estadounidense de gran capitalización Russell 1000®, efectiva después del cierre del mercado el 27 de junio de 2025, como parte de la reconstitución anual del índice de FTSE Russell. El índice Russell 1000® incluye aproximadamente 1,000 de los valores estadounidenses más grandes según la capitalización de mercado y es un referente clave para el desempeño de acciones de gran capitalización.
Según la CEO, la Dra. Helen Torley, esta inclusión refleja el liderazgo de la compañía en la administración rápida de dosis subcutáneas de gran volumen y su historial de crecimiento sólido tanto en ingresos como en beneficios. La membresía en el Russell 1000® se mantendrá por un año.
Halozyme Therapeutics (NASDAQ: HALO)는 FTSE Russell의 연례 지수 재구성의 일환으로 2025년 6월 27일 시장 마감 후 미국 대형주 Russell 1000® 지수에 편입되었음을 발표했습니다. Russell 1000® 지수는 시가총액 기준으로 미국 내 약 1,000대 대형주를 포함하며, 대형주 성과의 주요 벤치마크 역할을 합니다.
CEO인 헬렌 토를리 박사에 따르면, 이번 편입은 대용량 피하 투여 분야에서 회사의 선도적 위치와 견고한 매출 및 이익 성장 실적을 반영한 것입니다. Russell 1000® 지수 내 편입은 1년간 유지됩니다.
Halozyme Therapeutics (NASDAQ : HALO) a annoncé son intégration à l'indice américain des grandes capitalisations Russell 1000®, effective après la clôture des marchés le 27 juin 2025, dans le cadre de la reconstitution annuelle de l'indice FTSE Russell. L'indice Russell 1000® regroupe environ 1 000 des plus grandes valeurs américaines en fonction de leur capitalisation boursière et constitue un référentiel clé pour la performance des actions à grande capitalisation.
Selon la PDG, le Dr Helen Torley, cette inclusion reflète le leadership de l'entreprise dans la délivrance rapide de médicaments sous-cutanés en grande quantité ainsi que son historique de croissance durable du chiffre d'affaires et des bénéfices. L'appartenance à l'indice Russell 1000® restera en vigueur pendant un an.
Halozyme Therapeutics (NASDAQ: HALO) wurde im Rahmen der jährlichen Indexneuzuordnung von FTSE Russell mit Wirkung nach Börsenschluss am 27. Juni 2025 in den US-amerikanischen Large-Cap-Index Russell 1000® aufgenommen. Der Russell 1000® Index umfasst etwa 1.000 der größten US-Wertpapiere nach Marktkapitalisierung und dient als wichtiger Maßstab für die Performance von Large-Cap-Aktien.
Nach Angaben der CEO Dr. Helen Torley spiegelt diese Aufnahme die Führungsposition des Unternehmens bei der schnellen subkutanen Verabreichung großer Volumina von Medikamenten sowie die nachgewiesene nachhaltige Umsatz- und Gewinnsteigerung wider. Die Zugehörigkeit zum Russell 1000® Index bleibt für ein Jahr bestehen.
- Inclusion in the prestigious Russell 1000® Index, indicating significant market capitalization achievement
- Potential for increased visibility among institutional investors
- None.
The Russell 1000® Index includes approximately 1,000 of the largest
"Joining the Russell 1000 Index is an important milestone that reflects our leadership in rapid large-volume subcutaneous drug delivery and our track record of durable top-and-bottom line growth," said Dr. Helen Torley, President and CEO of Halozyme. "The inclusion will help to expand our visibility among the investment community as we continue to execute our strategy and deliver sustainable growth and profitability well into the future."
The Russell 1000® is managed by FTSE Russell, a global leader in index and analytics. Membership in the Russell 1000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the future execution of Halozyme's strategy and delivery of future sustainable growth and profitability, the durability of Halozyme's top and bottom line growth, the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results in the execution of Halozyme's strategy and unexpected future financial results and top and bottom line growth,. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com
Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-therapeutics-added-to-russell-1000-index-302494849.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
When will Halozyme (NASDAQ: HALO) be added to the Russell 1000 Index?
What does Halozyme's inclusion in the Russell 1000 Index mean for the company?
How long will Halozyme remain in the Russell 1000 Index?
What is the Russell 1000 Index and why is it important for Halozyme?
